UnknownPHASE2, PHASE3NCT04966234

A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection

Studying Aspergillosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Bambino Gesù Hospital and Research Institute
Principal Investigator
Adilia Warris, Prof
University of Exeter
Intervention
Posaconazole 100 MG [Noxafil](drug)
Enrollment
135 enrolled
Eligibility
8-17 years · All sexes
Timeline
20212023

Study locations (30)

Collaborators

University of Exeter · Radboud University Medical Center · Consorzio per Valutazioni Biologiche e Farmacologiche

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04966234 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis

← Back to all trials